PURPOSE: To compare the cost-effectiveness of (99m)Tc-methoxyisobutylisonitrile (MIBI) thyroid scintigraphy and the Afirma gene expression classifier for the assessment of cytologically indeterminate thyroid nodules. METHODS: A decision tree model was used. Costs were calculated from the perspective of the German health insurance system. The robustness of the results was assessed with probabilistic sensitivity analyses using a Monte Carlo simulation. RESULTS: Life expectancy was 34.3 years (estimated costs per patient €1,459 - €2,224) for the MIBI scan and 34.1 years (estimated costs €3,560 - €4,071) for the molecular test. These results were confirmed by the Monte Carlo simulation. CONCLUSION: MIBI thyroid scintigraphy is more cost-effective than the gene expression classifier.
PURPOSE: To compare the cost-effectiveness of (99m)Tc-methoxyisobutylisonitrile (MIBI) thyroid scintigraphy and the Afirma gene expression classifier for the assessment of cytologically indeterminate thyroid nodules. METHODS: A decision tree model was used. Costs were calculated from the perspective of the German health insurance system. The robustness of the results was assessed with probabilistic sensitivity analyses using a Monte Carlo simulation. RESULTS: Life expectancy was 34.3 years (estimated costs per patient €1,459 - €2,224) for the MIBI scan and 34.1 years (estimated costs €3,560 - €4,071) for the molecular test. These results were confirmed by the Monte Carlo simulation. CONCLUSION:MIBI thyroid scintigraphy is more cost-effective than the gene expression classifier.
Authors: Darya Chudova; Jonathan I Wilde; Eric T Wang; Hui Wang; Nusrat Rabbee; Camila M Egidio; Jessica Reynolds; Ed Tom; Moraima Pagan; C Ted Rigl; Lyssa Friedman; C Charles Wang; Richard B Lanman; Martha Zeiger; Electron Kebebew; Juan Rosai; Giovanni Fellegara; Virginia A LiVolsi; Giulia C Kennedy Journal: J Clin Endocrinol Metab Date: 2010-09-08 Impact factor: 5.958
Authors: Frederik A Verburg; Florian F Behrendt; Felix M Mottaghy; Alexander Heinzel Journal: Eur J Nucl Med Mol Imaging Date: 2013-10-11 Impact factor: 9.236
Authors: Erik K Alexander; Giulia C Kennedy; Zubair W Baloch; Edmund S Cibas; Darya Chudova; James Diggans; Lyssa Friedman; Richard T Kloos; Virginia A LiVolsi; Susan J Mandel; Stephen S Raab; Juan Rosai; David L Steward; P Sean Walsh; Jonathan I Wilde; Martha A Zeiger; Richard B Lanman; Bryan R Haugen Journal: N Engl J Med Date: 2012-06-25 Impact factor: 91.245
Authors: Henry Li; Karen A Robinson; Blair Anton; Ian J Saldanha; Paul W Ladenson Journal: J Clin Endocrinol Metab Date: 2011-08-24 Impact factor: 5.958
Authors: Chung-Che Charles Wang; Lyssa Friedman; Giulia C Kennedy; Hui Wang; Electron Kebebew; David L Steward; Martha A Zeiger; William H Westra; Yongchun Wang; Elham Khanafshar; Giovanni Fellegara; Juan Rosai; Virginia Livolsi; Richard B Lanman Journal: Thyroid Date: 2010-12-29 Impact factor: 6.568
Authors: L Giovanella; A Campenni; G Treglia; F A Verburg; P Trimboli; L Ceriani; M Bongiovanni Journal: Eur J Nucl Med Mol Imaging Date: 2015-12-23 Impact factor: 9.236
Authors: Salvatore Sciacchitano; Luca Lavra; Alessandra Ulivieri; Fiorenza Magi; Gian Paolo De Francesco; Carlo Bellotti; Leila B Salehi; Maria Trovato; Carlo Drago; Armando Bartolazzi Journal: Oncotarget Date: 2017-07-25
Authors: Stefano Valabrega; Giuliano Santolamazza; Francesco Romanelli; Giorgia Scapicchio; Francesco D'Angelo; Carlo Bellotti; Paolo Aurello; Luciano Izzo; Maria R Giovagnoli; Pierpaolo Trimboli Journal: Front Endocrinol (Lausanne) Date: 2018-07-10 Impact factor: 5.555